Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Verdiperstat

Generic Name: Verdiperstat

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₅N_₃O_₂S

CAS Number: 890655-80-8

Unique Ingredient Identifier: TT3345YXVR

Overview

Verdiperstat has been used in trials studying the basic science and treatment of Multiple System Atrophy (MSA).

Background

Verdiperstat has been used in trials studying the basic science and treatment of Multiple System Atrophy (MSA).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

Phase 1

Recruiting

Posted: 2022/01/11

Sponsor:

Peter Ljubenkov, MD

ID:NCT05184569

Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

Posted: 2021/10/20

Sponsor:Biohaven Pharmaceuti...

ID:NCT05086094

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

Early Phase 1

Completed

Posted: 2020/11/05

Sponsor:Brigham and Women's ...

ID:NCT04616456

HEALEY ALS Platform Trial - Regimen B Verdiperstat

Phase 2

Completed

Posted: 2020/06/18

Sponsor:

Merit E. Cudkowicz, ...

ID:NCT04436510

Study of BHV-3241 in Participants With Multiple System Atrophy

Phase 3

Completed

Posted: 2019/05/16

Sponsor:Biohaven Pharmaceuti...

ID:NCT03952806

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Biohaven Secures $600 Million Non-Dilutive Funding from Oberland Capital for Rare Disease Drug Development

a month ago

Biohaven Ltd. has entered into a $600 million non-dilutive funding agreement with Oberland Capital, with an initial $250 million tranche expected by April 30, 2025.

FDA Lifts Clinical Hold on Amylyx's AMX0114 Phase 1 ALS Trial, Paving Way for LUMINA Study

4 months ago

The FDA has lifted the clinical hold on Amylyx Pharmaceuticals' Phase 1 trial of AMX0114, an antisense oligonucleotide for ALS treatment.

Denali Therapeutics' DNL343 Fails to Meet Primary Endpoint in HEALEY ALS Platform Trial

5 months ago

Denali Therapeutics' DNL343, an eIF2B agonist, did not meet the primary endpoint of slowing ALS disease progression in a Phase 2/3 trial.

HEALEY ALS Platform Trial: Streamlining Drug Development for Amyotrophic Lateral Sclerosis

6 months ago

The HEALEY ALS Platform Trial is pioneering a new approach to accelerate the development of effective treatments for amyotrophic lateral sclerosis (ALS).

New Drug Development Pipeline Shows Promise for ALS Treatment with 53 Candidates Under Investigation

2 years ago

A comprehensive review of ALS drug development reveals 53 new drug candidates in clinical trials between 2020-2022, with 13 compounds advancing to Phase 3 trials and showing promising therapeutic potential.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy